Cardiol Therapeutics
clinical stage biotech co. developing innovative therapies for inflammatory heart disease
🤖
AI Overview
With $310K in lobbying spend across 9 quarterly filings, Cardiol Therapeutics is an active lobbying client. Their lobbying covers 1 issue area. Active from 2020 to 2022.
$310K
Total Spend
3
Years Active
1
Firms Hired
1
Lobbyists Deployed
1
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2020 | $30K |
| 2021 | $160K |
| 2022 | $120K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: MED
- •DEA's Interim Final Rule on 2018 Farm Bill as it relates to CBD, and Cardiol's Phase 2/3 FDA IND approved clinical trial for potential covid therapeutic.
- •Determining the control status of synthetically derived cannabidoil from the language and intent of the Implementation of the Agriculture Improvement Act of 2018.
- •No specific lobbying issues this quarter, determining applicable research grant opportunities
- •No specific lobbying issues this quarter.
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.